Ftse Mib
34.174,18
-0,20%
DAX
18.502,72
0,35%
S&P 500
5.187,70
0,13%
NASDAQ
0,00
0,00%
Bitcoin
62.271,85
-0,10%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Aeglea BioTherapeutics Inc (AGLE) Aeglea BioTherapeutics Inc (AGLE) Notizie

AGLE

Aeglea BioTherapeutics (AGLE)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:AGLE
DataOraFonteTitoloSimboloCompagnia
30/04/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:AGLEAeglea BioTherapeutics Inc
25/04/202422:55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AGLEAeglea BioTherapeutics Inc
25/04/202422:40Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:AGLEAeglea BioTherapeutics Inc
25/04/202422:21Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AGLEAeglea BioTherapeutics Inc
02/04/202422:36Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:AGLEAeglea BioTherapeutics Inc
01/04/202422:06Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:AGLEAeglea BioTherapeutics Inc
20/03/202412:14Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:AGLEAeglea BioTherapeutics Inc
18/03/202421:06Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:AGLEAeglea BioTherapeutics Inc
14/03/202421:12Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:AGLEAeglea BioTherapeutics Inc
27/11/202322:32Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:AGLEAeglea BioTherapeutics Inc
27/11/202314:30PR Newswire (US)Aeglea BioTherapeutics Announces Name Change to Spyre Therapeutics, Appoints CEO and Additional Directors, and Expands Leadership Team to Develop Next-Generation Therapeutic Combinations for the Treatment of IBDNASDAQ:AGLEAeglea BioTherapeutics Inc
22/11/202323:00PR Newswire (US)Aeglea BioTherapeutics Announces Grants of Inducement AwardsNASDAQ:AGLEAeglea BioTherapeutics Inc
15/11/202323:18Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:AGLEAeglea BioTherapeutics Inc
14/11/202321:13Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:AGLEAeglea BioTherapeutics Inc
09/11/202322:10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AGLEAeglea BioTherapeutics Inc
09/11/202322:05PR Newswire (US)Aeglea BioTherapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:AGLEAeglea BioTherapeutics Inc
31/10/202301:00PR Newswire (US)Aeglea BioTherapeutics to Participate in Upcoming November Investor ConferencesNASDAQ:AGLEAeglea BioTherapeutics Inc
07/10/202303:40Edgar (US Regulatory)Form PRER14A - Preliminary Proxy Soliciting materialsNASDAQ:AGLEAeglea BioTherapeutics Inc
14/09/202323:03PR Newswire (US)Aeglea BioTherapeutics to Participate in Upcoming September ConferenceNASDAQ:AGLEAeglea BioTherapeutics Inc
07/09/202314:40PR Newswire (US)Aeglea BioTherapeutics Announces Reverse Stock SplitNASDAQ:AGLEAeglea BioTherapeutics Inc
05/09/202313:00PR Newswire (US)Aeglea BioTherapeutics Expands Executive Leadership Team with Appointment of Industry Veterans Scott Burrows and Heidy Abreu King-JonesNASDAQ:AGLEAeglea BioTherapeutics Inc
11/08/202313:00PR Newswire (US)Aeglea BioTherapeutics Reports Second Quarter 2023 Financial ResultsNASDAQ:AGLEAeglea BioTherapeutics Inc
07/08/202322:25Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:AGLEAeglea BioTherapeutics Inc
27/07/202313:00PR Newswire (US)Aeglea BioTherapeutics Announces Sale of Pegzilarginase to Immedica PharmaNASDAQ:AGLEAeglea BioTherapeutics Inc
06/07/202322:04Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:AGLEAeglea BioTherapeutics Inc
30/06/202323:24Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:AGLEAeglea BioTherapeutics Inc
23/06/202322:30PR Newswire (US)Aeglea BioTherapeutics Announces Grant of Inducement AwardsNASDAQ:AGLEAeglea BioTherapeutics Inc
23/06/202315:18Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:AGLEAeglea BioTherapeutics Inc
22/06/202314:17PR Newswire (US)Aeglea BioTherapeutics Announces Acquisition of Spyre TherapeuticsNASDAQ:AGLEAeglea BioTherapeutics Inc
11/05/202313:06Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:AGLEAeglea BioTherapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:AGLE

La tua Cronologia

BIT
UCG
Unicredit
BIT
RACE
Ferrari NV
BIT
STLAM
Stellantis NV
BIT
LDO
Leonardo
BIT
ISP
Intesa Sanpaolo
BIT
ENEL
Enel
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
BAMI
Banco BPM
BIT
ENI
Eni
BIT
CPR
Davide Campari
BIT
BPE
Bper Banca
BIT
FBK
Finecobank
BIT
IRE
Iren
BIT
STMMI
ST Microelectronics
BIT
SPM
Saipem
BIT
G
Generali
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network